Fulphila

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Fierce Pharma
Tue, 06/5/18 - 12:02 pm
FDA
Fulphila
Mylan Labs
biosimilars
Amgen
Neulasta